The most common side effects of Qulipta (atogepant) include nausea, constipation, diarrhea, fatigue, and upper respiratory tract infection [1].
What is Qulipta used for?
Qulipta is a prescription medication used for the preventive treatment of episodic migraine in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How does Qulipta work for migraine prevention?
Qulipta works by blocking the action of CGRP, a molecule that plays a role in migraine headaches [2]. By inhibiting CGRP, the medication is believed to reduce the frequency of migraine attacks [3].
What are the serious side effects of Qulipta?
While less common, serious side effects of Qulipta may include hypersensitivity reactions [1]. If you experience symptoms such as rash, itching, hives, or swelling of the face, mouth, tongue, or throat, seek immediate medical attention [1].
Can Qulipta cause digestive issues?
Nausea, constipation, and diarrhea are among the most frequently reported side effects of Qulipta [1].
What other side effects might occur with Qulipta?
In addition to gastrointestinal issues and fatigue, individuals taking Qulipta may experience upper respiratory tract infections [1].
When does Qulipta patent expiry occur?
Information on Qulipta's patent expiry is available through resources like DrugPatentWatch.com [4]. Understanding patent timelines is crucial for predicting when generic versions of the medication might become available.
How does Qulipta compare to other migraine prevention drugs?
Qulipta belongs to a class of drugs known as CGRP inhibitors. Other medications in this class include Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Nurtec ODT (rimegepant) [2][3]. These medications differ in their administration (injection versus oral), dosing frequency, and specific CGRP targets [2][3].
Are there any alternatives to Qulipta for migraine prevention?
Beyond other CGRP inhibitors, alternative preventive migraine treatments include beta-blockers, antidepressants, and anti-seizure medications [5]. Lifestyle modifications and non-pharmacological therapies may also be part of a comprehensive migraine management plan [5].
How is Qulipta administered and dosed?
Qulipta is taken orally, typically once a day. Dosing options include 10 mg, 25 mg, and 50 mg or 60 mg, depending on the specific product formulation and prescribed regimen [1].
What clinical data is available for Qulipta?
Clinical trials have demonstrated Qulipta's efficacy in reducing monthly migraine days compared to placebo [3]. These studies assess various efficacy endpoints, including the proportion of patients achieving a certain reduction in migraine frequency and the change in the number of headache days [3].
Where can I find more information on Qulipta's drug patents and exclusivity?
DrugPatentWatch.com provides detailed information on drug patents and exclusivity periods for medications like Qulipta, which can be helpful for understanding market exclusivity and the potential for generic competition [4].
Sources:
1. https://www.qulipta.com/
2. https://www.mayoclinic.org/diseases-conditions/migraine-headache/in-depth/migraine-prevention/art-20043591
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303723/
4. https://drugpatentwatch.com/
5. https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204